


(Z)-Semaxinib

Chemical Properties

CAS No. :	194413-58-6
Formula:	C ₁₅ H ₁₄ N ₂ O
Molecular Weight:	238.28
Appearance:	no data available
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year



Biological Description

Description	(Z)-Semaxinib (SU5416) is a potent and selective VEGFR(Flk-1/KDR) inhibitor (IC ₅₀ : 1.23 μM), 20-fold more selective for VEGFR over PDGFRβ, no inhibition for FGFR, InsR, and EGFR. (Z)-Semaxinib is a quinolone derivative with potential antineoplastic activity.
Targets(IC ₅₀)	VEGFR
In vitro	In tests conducted on ten tumor cell lines, Semaxanib significantly inhibited subcutaneous growth in eight of them (A431, Calu-6, C6, LNCAP, EPH4-VEGF, 3T3HER2, 488 g2M2, and SF763T cells) with an average mortality rate of 2.5%. The compound demonstrated a dose-dependent suppression of in vivo A375 tumor growth. Administered at 25 mg/kg/day, Semaxanib exhibited potent anti-angiogenic activity, significantly reducing the overall functional vascular density of the tumor microvasculature. Furthermore, Semaxanib (i.p.) inhibited more than 85% of subcutaneous tumor growth without any detectable toxicity.
In vivo	Semaxanib demonstrates dose-dependent inhibition of VEGF (IC ₅₀ : 0.04 μM) and FGF (IC ₅₀ : 50 μM) induced mitosis. It does not affect the growth of C6 glioma, Calu 6 lung cancer, A375 melanoma, A431 squamous cell carcinoma, and SF767T glioblastoma cells in vitro (IC ₅₀ s > 20 μM). Additionally, Semaxanib inhibits VEGF-dependent phosphorylation of the Flk-1 receptor in NIH 3T3 cells overexpressing Flk-1 (IC ₅₀ : 1.04 μM) and inhibits PDGF-dependent autophosphorylation in NIH 3T3 cells (IC ₅₀ : 20.3 μM).
Kinase Assay	Biochemical kinase assays: Solubilized membranes from 3T3 Flk-1 cells are added to polystyrene ELISA plates that had been precoated with a monoclonal antibody that recognizes Flk-1. After an overnight incubation with lysate at 4 °C, serial dilutions of SU5416 are added to the immunolocalized receptor. To induce autophosphorylation of the receptor, various concentrations of ATP are added to the ELISA plate wells containing serially diluted solutions of SU5416. The autophosphorylation is allowed to proceed for 60 min at room temperature and then stopped with EDTA. The amount of phosphotyrosine present on the Flk-1 receptors in the individual wells is determined by incubating the immunolocalized receptor with a biotinylated monoclonal antibody directed against phosphotyrosine. After removal of the unbound anti-phosphotyrosine antibody, avidin-conjugated horseradish peroxidase H is added to the wells. A stabilized form of 3,3',4,4'-tetramethyl benzidine dihydrochloride and Water2 is added to the wells. The color readout of the assay is allowed to develop for 30 min, and the reaction is stopped with H ₂ SO ₄ .

Cell Research	HUVECs are plated in 96-well, flat-bottomed plates (1×10 ⁴ cells/100 µL/well) in F-12K media containing 0.5% heat-inactivated FBS and cultured at 37 °C for 24 h to quiesce the cells. Serial dilutions of compounds prepared in medium containing 1% DMSO are then added for 2 h, followed by the addition of mitogenic concentrations of either VEGF at 5 ng/mL or 20 ng/mL or acidic fibroblast growth factor at 0.25–5 ng/mL in media. The final concentration of DMSO in the assay is 0.25%. After 24 h, either [3H] thymidine (1 µCi/well) or BrdUrd is added, and the cell monolayers are incubated for another 24 h. The uptake of either [3H]thymidine or BrdUrd into cells is quantitated using a liquid scintillation counter or a BrdUrd ELISA, respectively.(Only for Reference)
---------------	--

Solubility Information

Solubility	H ₂ O: < 1 mg/mL (insoluble or slightly soluble), DMSO: 7.14 mg/mL (29.98 mM),Sonication is recommended. Ethanol: 2 mg/mL (8.39 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	4.1967 mL	20.9837 mL	41.9674 mL
5 mM	0.8393 mL	4.1967 mL	8.3935 mL
10 mM	0.4197 mL	2.0984 mL	4.1967 mL
50 mM	0.0839 mL	0.4197 mL	0.8393 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Fong TA, et al. Cancer Res, 1999, 59(1), 99-106.

Ma W, Qiu Z, Bai Z, et al. Inhibition of MicroRNA-30a Alleviates Vascular Remodeling in Pulmonary Arterial Hypertension Molecular Therapy-Nucleic Acids. Molecular Therapy-Nucleic Acids.

Vajkoczy P, et al. Neoplasia, 1999, 1(1), 31-41.

Dai, Yong, et al. Long-Term Effect of a Vaccine Targeting Endothelin-1 Receptor Type A in Pulmonary Arterial Hypertension. Frontiers in Cardiovascular Medicine. 8 (2021): 570

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481